Medical Marijuana

FDA’s Approval of New Cannabis-Derived Drug Will Pave the Way for Future Medications, CEO Says

Health & Fitness Industry Marijuana Laws, Regulations, & Politics Medical Marijuana National & Federal Marijuana News Science & Tech US Marijuana News June 27, 2018

Edmonton, AB – June 26, 2018 – PRESS RELEASE – Aurora Cannabis Inc. announced today that it has agreed to a new $200 million debt facility, with a potential upsize to $250 million, with the Bank of Montreal (“BMO”). The facility will consist of a $150 million term loan and... Read more

Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845

Marijuana Stocks, Finance, & Investing Medical Marijuana June 27, 2018

Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced positive top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries. At the... Read more

BREAKING NEWS: Epidiolex, First Non-Synthetic Cannabis Drug, Approved

Health & Fitness Marijuana Laws, Regulations, & Politics Medical Marijuana National & Federal Marijuana News US Marijuana News June 25, 2018

Big win today for GW Pharma. In a previous post, we discussed GW Pharmaceuticals, the leading developer of cannabis-based pharmaceuticals. Today, the FDA announced the approval of GW Pharmaceutical’s drug Epidiolex (cannabidiol), an oral solution for treatment of seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome and... Read more

InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter’s Over-Allotment Option

Marijuana Stocks, Finance, & Investing Medical Marijuana June 21, 2018

InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has closed the “bought deal” financing originally announced on June 12, 2018, and that... Read more

InMed Pharmaceuticals announces increase in Bought Deal offering to $13 million

Marijuana Stocks, Finance, & Investing Medical Marijuana June 12, 2018

InMed Pharmaceuticals Inc. (TSX:IN) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase, as underwriter, 14,444,560 units of the Company, on a “bought deal” basis pursuant to the filing of a shelf prospectus... Read more

Medical Cannabis Leadership from Canopy Growth and Subsidiary Spectrum Cannabis

Marijuana Stocks, Finance, & Investing Medical Marijuana June 12, 2018

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to provide the following updates on its medical cannabis program and to re-affirm its strong commitment to medical cannabis, the patients who depend on it, and the Healthcare Professionals who prescribe it. HISTORIC CLINICAL TRIAL MILESTONES Marking a major milestone for medical... Read more

FDA’s Approval of New Cannabis-Derived Drug Will Pave the Way for Future Medications, CEO Says

Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845

BREAKING NEWS: Epidiolex, First Non-Synthetic Cannabis Drug, Approved

InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter’s Over-Allotment Option

InMed Pharmaceuticals announces increase in Bought Deal offering to $13 million

Medical Cannabis Leadership from Canopy Growth and Subsidiary Spectrum Cannabis

With Deadline Looming, New Hampshire Marijuana Legalization Conference Committee Makes Slow Progress Toward Deal

Ahead Of Hearing On New Jersey Psilocybin Bill, Majority Of State Residents Back Legalization For Therapeutic Use In New Poll

VP Kamala Harris says cannabis isn’t a “gateway drug” (Newsletter: June 6, 2024)

Cannabis M&A: Protecting Against Undisclosed Liabilities

Alabama Medical Marijuana Grower Nears First Harvest, But Litigation Is Still Blocking Patient Access

The Green Organic Dutchman Signs a Commercial Sublicense with EnWave and Tilray to Dry Cannabis in Canada